9620NomuBalanced
BALSM MEDICAL
شركة بلسم الأفق الطبية
Fair Value (median)
14.79 SAR
Current Price
24.19
Fair
Now
Overvalued
Premium +63.5%· upside -38.9%
Blended from: Graham
Health Check
34.6
Overall / 100
Value0
Future20
Past41.8
Health76.7
Dividend0
Value0/100
Trades about 63.5% above its estimated fair value.
- Discount to fair value
- -63.5%
- Price to book
- —
- Fair-value confidence
- —
Future20/100
Modest growth of about 8% a year is expected.
- Forecast growth (rev.)
- 8%
- Revenue CAGR (2y)
- 6.3%
- Earnings CAGR (2y)
- -31.2%
Past41.8/100
A steady, profitable operating history.
- Return on equity
- 6.4%
- Net margin
- 9.7%
- Earnings CAGR (2y)
- -31.2%
- Profitable years
- 3/3
Health76.7/100
Strong balance sheet — cash covers total debt.
- Debt to equity
- 4.9%
- Net debt to equity
- -30.2%
- Cash covers total debt
- Yes
- Free cash flow
- Negative
Dividend0/100
Pays no dividend.
- Dividend yield
- —
Rewards
- Healthy balance sheet.
Risks
- Trades 63.5% above estimated fair value.
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Dividend return (if you buy today)
This company doesn’t currently pay a dividend, so there’s no income return to project. The fair-value gauge above covers the price side.
Historical Wealth Simulator
Invest a fixed amount every year and see what it would be worth today.
If you invested 1,000.00 annually starting 2024، your value today is 3,508.51. You put in 3,000.00 over 3 years. Total return: +17.0% (+2.4% Dividends، +14.5% Capital gain).
Invested
3,000.00 SAR
Dividends
73.05 SAR
Capital gain
435.46 SAR
InvestedCapital gainDividends— dashes = cost basistap a bar for figures
Split-adjusted prices; dividends taken as cash (not reinvested). Past performance isn’t a forecast.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for details
Valuation breakdown
Fair value = median of the applicable methods (Graham).
Discounted Cash Flow
Excluded — non-positive free cash flow
N/A
Dividend Discount Model
Excluded — company pays no dividend
N/A
Graham Number
Tap to adjust assumptions
14.79 SAR
Fair Value (median)14.79 SAR
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 10.50%
- CAPM cost of equity
- 10.50%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Dividend history
Dividend / share & historical yield (SAR).
Dividend / share yield %tap a bar for figures
Quarterly dividends & yield
Per-share dividends by quarter, full-year total, and yield on the year's average price · SAR
| Year | Q1 | Q2 | Q3 | Q4 | Full year | Yield (avg) |
|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | — |
| 2025 | — | — | — | — | — | — |
| 2024 | 0.30 | 0.30 | 0.30 | 0.30 | 1.20 | 3.2% |
| 2023 | 0.10 | 0.10 | 0.10 | 0.10 | 0.38 | — |
Key figures
| Metric | FY'23 | FY'24 | FY'25 |
|---|---|---|---|
| Revenue | 18.03M | 19.86M | 20.38M |
| Net Income | 4.16M | 4.78M | 1.97M |
| Net Margin | 23.1% | 24.1% | 9.7% |
| Operating Cash Flow | 5.41M | 5.48M | -2.94M |
| OCF Margin | 30.0% | 27.6% | -14.4% |
| Capital Expenditure | 7.15M | 210.7K | 4.15M |
| Free Cash Flow | -1.74M | 5.27M | -7.10M |
| FCF Margin | -9.7% | 26.5% | -34.8% |
| FCF Conversion | -41.8% | 110.3% | -360.7% |
| EPS (Diluted) | 1.66 | 1.91 | 0.79 |
| Dividend / Share | 0.38 | 1.20 | 0.00 |
Corporate actions
SStock Split
2×2025-12-22
Community Notes0
No notes yet. Be the first to share a thesis.